Zisun Chinese Pharm

Jiangsu Zisun Pharmaceutical, a subsidiary of the Hongdou Group, is a specialized pharmaceutical company focused on the research, development, and production of anti-tumor drugs, particularly taxanes. The company leverages one of the world's largest Taxus chinensis plantations to ensure a sustainable and high-quality supply of raw materials for Paclitaxel production. Zisun Pharmaceutical operates an integrated value chain encompassing cultivation, API extraction, and the manufacturing of finished dosage forms. Their commercial portfolio includes oncology treatments such as Paclitaxel and Docetaxel injections, as well as advanced formulations like albumin-bound paclitaxel. The company is GMP-certified and provides both proprietary products and CDMO services to the global pharmaceutical industry. Their strategic focus remains on oncology and the development of high-barrier generic and innovative formulations.